Zacks Investment Research·5d ago
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should KnowAdma Biologics (ADMA) closed the most recent trading day at $9.13, moving +2.01% from the previous trading session.
ADMA Biologics has demonstrated a remarkable operational turnaround, with gross margins expanding from 47.8% in 2024Q1 to 69.4% in 2026Q2, driven by a favorable product mix shift toward premium ASCENIV sales. The company has achieved sustained profitability, w...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $0.16-2.0% vs $0.16 | $124M-0.8% vs $125M |
Q2 2026 May 6, 2026 | $0.19-1.7% vs $0.19 | $114M-18.2% vs $140M |
Q1 2026 Feb 25, 2026 | $0.20+8.1% vs $0.18 | $139M-0.3% vs $140M |
Q4 2025 Nov 5, 2025 | $0.16+0.0% vs $0.16 | $134M-4.0% vs $140M |
Adma Biologics (ADMA) closed the most recent trading day at $9.13, moving +2.01% from the previous trading session.
Philadelphia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite declining demand for its flagship product, ASCENIV.
Adma Biologics (ADMA) reached $9.23 at the closing of the latest trading day, reflecting a -1.7% change compared to its last close.
Adma Biologics (ADMA) closed at $9.36 in the latest trading session, marking a -1.01% move from the prior day.
Benchmark ADMA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ADMA Biologics, Inc. (ADMA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $9.70 | $2.25B | 16.17 | 19.63% | 28.8% | 35.56% | — | |
| $7.20 | $6.09B | 11.09 | 0.2% | 6.09% | 5.84% | — | |
| $378.88 | $10.2B | 13.59 | 0.65% | 8.59% | 3.15% | — | |
| $0.01 | $126.15K | -0.01 | -35.82% | -717.43% | -1358.66% | — | |
| $112.44 | $13.34B | 43.92 | 37.55% | 24.86% | 180.63% | — | |
| $323.96 | $13.11B | 18.92 | 0.33% | 14.21% | 41.06% | — |
ADMA Biologics, Inc. (ADMA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ADMA Biologics, Inc. (ADMA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 2, 2026·SEC
May 6, 2026·SEC
Get notified when ADMA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ADMA Biologics, Inc. (ADMA) stock FAQ — growth, dividends, profitability & financials explained
ADMA Biologics, Inc. (ADMA) reported $512.3M in revenue for fiscal year 2025.
ADMA Biologics, Inc. (ADMA) grew revenue by 19.6% over the past year. This is strong growth.
Yes, ADMA Biologics, Inc. (ADMA) is profitable, generating $169.0M in net income for fiscal year 2025 (28.8% net margin).
ADMA Biologics, Inc. (ADMA) has a return on equity (ROE) of 35.6%. This is excellent, indicating efficient use of shareholder capital.
ADMA Biologics, Inc. (ADMA) generated $116.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
